K
Kuur Therapeutics
Manufactures cellular immunotherapeutics in order to treat cancer and infectious diseases
About Kuur Therapeutics
Kuur Therapeutics is a pioneering biotech startup focused on revolutionizing cancer treatment through advanced cell therapy. The company specializes in developing engineered CAR NKT cell therapies, which are designed to target and destroy cancer cells. CAR stands for Chimeric Antigen Receptor, a technology that modifies immune cells to better recognize and attack cancer. NKT cells, or Natural Killer T cells, are a unique subset of immune cells known for their ability to kill cancer cells. Kuur Therapeutics operates in the highly specialized field of immunotherapy, which involves using the body's own immune system to fight diseases like cancer. The company serves patients suffering from both hematological (blood-related) and solid tumors. Their therapies are "off the shelf," meaning they are readily available and do not require customization for each patient, which can significantly reduce treatment time and costs. The business model of Kuur Therapeutics revolves around research, development, and commercialization of these innovative therapies. They generate revenue through licensing agreements and partnerships with other biotech firms and medical institutions. By collaborating with renowned entities like Baylor College of Medicine and Texas Hospital, Kuur Therapeutics leverages global expertise to advance their research and bring their products to market. Kuur Therapeutics has already made significant strides, including dosing the first patients with their allogeneic (donor-derived) CAR NKT cell therapy and publishing promising interim Phase 1 data. The company is actively seeking further licensing and partnership opportunities to expand the therapeutic possibilities of their NKT cell immunotherapy products. In summary, Kuur Therapeutics is at the forefront of cancer treatment innovation, offering a unique and potentially transformative approach to immunotherapy.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 80.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, UKSU, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Jul 2016
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2021 | $75M | $185M | Athenex | ↗ |
| FundingOther financing | Jan 2021 | $0 | — | Salica Investments | — |
Growth signals
Latest recorded traffic for Kuur Therapeutics is 0 monthly website visits. Kuur Therapeutics's team grew 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
SpireaAdvanced antibody-drug conjugate technology for cancer therapeutics |
Harrogate, United Kingdom | Operational | 8 | $3.8M | $13M |
DJS AntibodiesAntibody therapeutics for chronic inflammatory and fibrotic diseases |
Oxford, United Kingdom | Acquired | |||
Argonaut TherapeuticsDeveloping epigenetic therapies targeting abnormal arginine methylation |
Oxford, United Kingdom | Acquired | |||
FemtogenixDNA-interactive payloads for antibody-drug conjugates |
St Albans, United Kingdom | Operational | |||
Oxford VacmedixDevelop therapeutic agents for the treatment of cancer |
Oxford, United Kingdom | Operational | |||
AutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases |
London, United Kingdom | Operational | |||
IGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors |
London, United Kingdom | Operational | |||
KinomicaPhosphoproteomic diagnostic platform for precision oncology therapy selection |
Macclesfield, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kuur Therapeutics in the Houston ecosystem
The Kuur Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Cancer Prevention and Research Institute of Texas (CPRIT)
Series A3 investors entered at this stage
Wellcome Trust
Imperial Innovations
Woodford Investment Management
Series B and later3 investors entered at this stage
Invesco
Invesco Perpetual
Touchstone Innovations
Other known investors4 additional known investors
Athenex
College of Medicine and Integrated Health
Imperial College London
Salica Investments
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kuur Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kuur Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











